In 2024, a sphere the size of a baseball rolled across the moon's dusty surface, unfolding like a miniature mechanical flower to explore what no palm-sized rover had conquered before. Japan's SLIM lander deployed LEV-2, a transformable rover that arrived on the lunar surface in tight spherical form, then expanded wheels and cameras to autonomously navigate the powdery terrain for two hours—a feat that required an unusual partnership between the Japanese space agency JAXA and Tomy, the toy manufacturer famous for transforming ball robots.
The challenge LEV-2 solved is deceptively simple but technically formidable: tiny rovers struggle to move through soft lunar regolith because wheels sink and lose traction. Microbots are ideal for deep-space missions—they weigh almost nothing and take up minimal room on a lander—but their smallness becomes a liability on powder. JAXA's insight was that Tomy's decades of engineering compact, shape-shifting toys had already cracked the physics problem. By deploying wheels that rotate on an off-center axis, LEV-2 achieves a powder-traversing stride that larger rovers cannot match.
The rover captured high-resolution images of the moon's surface and the SLIM lander itself, transmitting data back through the lander to JAXA. The mission demonstrated something profound: extremely compact micro-robots are not just feasible for exploring Earth's moon—they're viable across the solar system. This opens new possibilities for cost-effective, lightweight surface exploration on planets, moons, and asteroids where size and weight matter most.
Meanwhile, on Earth, researchers have finally solved a medical mystery that has haunted immunologists for decades. A new study involving data from over 4,900 patients has identified the root cause of inflammatory bowel disease, the condition that encompasses Crohn's disease and ulcerative colitis and typically strikes people in adolescence or early adulthood. The culprit is an autoimmune attack on interleukin-10, a protein that normally guards the immune system from overreacting. When the immune system wrongly produces antibodies against interleukin-10, uncontrolled gut inflammation follows.
The findings are striking in their specificity: researchers found high levels of interleukin-10-neutralizing antibodies in 3.5% of patients with Crohn's and ulcerative colitis, but in none of the healthy control subjects. "We've suspected an important role of interleukin-10 in patients with inflammatory bowel disease for decades. The study now provides clear evidence and contributes the missing link between a well-known genetic variant and the very recently discovered autoimmunity to interleukin-10," says Professor Holm Uhlig of the University of Oxford. This clarity matters because it could transform how clinicians diagnose and treat millions of people worldwide with personalized approaches based on their immune profiles.
In neuroscience, Yale researchers have cracked another long-standing puzzle: why two-thirds of people struggle to master brain-computer interfaces. Their breakthrough came from recognizing that the brain doesn't operate like a freshly programmable computer—it follows well-worn neural pathways shaped by evolution and experience. Rather than forcing participants to rewire their brains to match the machine, the Yale team built an interface that adapts to each person's unique neural geometry. Using functional magnetic resonance imaging to map individual brain activity while participants played video games, they created algorithms that translate natural brain patterns into avatar movement. The results were transformative: participants achieved control in less than one hour of training, and their brains reorganized themselves to align even more closely with what the interface required. For millions living with paralysis or neurological conditions, this adaptive approach offers genuine hope.